Boston, MA 09/18/2014 (wallstreetpr) – According to reports, pharmaceutical giant Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) has decided to enter into a licensing agreement with Merck & Co., Inc. (NYSE:MRK). The deal has been signed keeping Tildrakizumab in context. It is one of the well-acclaimed investigational therapeutic antibody candidates in the world that is to be used by the company for the treatment of plaque psoriasis.
Insights of the agreement deal:
As per the reports, SUNPHARMA will buy the worldwide rights of Tildrakizumab from MRK. After the deal, SUNPHARMA will be able to use and sell it for all human indications in any part of the world. The company has signed this deal in $80 million upfront payment. According to reports, scientist is testing Tildrakizumab in Phase III registration trials. If everything goes fine, then soon it will be used for the treatment of chronic plaque psoriasis, which is a skin ailment. As per the information revealed by the management, after the execution of deal Merck & Co., Inc. (NYSE:MRK) will continue all the regulatory activities and clinical development. The entire cost of these activities will be afforded by Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA). As soon as the product is ready and approved, then SUNPHARMA will take charge of all the regulatory activities such as subsequent submissions, post-approval studies, pharma-co-vigilance, commercialization and manufacturing of the product.
After signing of the agreement, Merck & Co., Inc. (NYSE:MRK) is eligible all the undisclosed payments associated with sales and regulatory milestones. It also includes product approval. Other than these undisclosed payments, MRK will also receive tiered royalties on sales of the product across the globe. The management of MRK seemed very pleased after the execution of this license agreement. Iain D Dukes, Senior Vice President, Licensing and Research Laboratories Business Development said that it was a proud moment for the firm to sign a deal with Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA). He was very pleased saying that with the help of this agreement, Merck & Co., Inc. (NYSE:MRK) would be able to help many who suffered from chronic plaque psoriasis.
